Basic and clinical studies on S-1108 in urinary tract infections

Noriaki Ono; Toyohiko Watanabe; Tadasu Takenaka; Toshihide Hayashi; Kazuhiro Hata; Hiromi Kumon; Hiroyuki Ohmori; Katsuiehi Nanba; Yoshikatsu Kondou; Teruhisa Ohhashi; Teruaki Akaeda

doi:10.11250/chemotherapy1953.41.Supplement1_448

Basic and clinical studies on S-1108 in urinary tract infections

Noriaki Ono, Toyohiko Watanabe, Tadasu Takenaka, Toshihide Hayashi, Kazuhiro Hata, Hiromi Kumon, Hiroyuki Ohmori, Katsuiehi Nanba, Yoshikatsu Kondou, Teruhisa Ohhashi, Teruaki Akaeda

Research output: Contribution to journal › Article › peer-review

Abstract

We studied the antibacterial activity and efficacy of S-1108, a new cephem antibiotic, in urinary tract infections. 1) Antibacterial activity : The MICs of S-1006 were measured against 202 clinical isolates of 14 species from urinary tract infections and compared with those of cefaclor (CCL), cefixime (CFIX) and cefteram (CFTM). In general, the antibacterial activity of S-1006 was almost equal to that of CFIX and CFTM, but superior to that of CCL. 2) Clinical efficacy : According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 84.2% (16/19) for chronic complicated UTI. Bacteriologically, 21 of the 22 strains isolated (95.4%) were eradicated. 3) Side effects : No clinical adverse reactions and no abnormal laboratory findings were observed.

Original language	English
Pages (from-to)	448-455
Number of pages	8
Journal	CHEMOTHERAPY
Volume	41
DOIs	https://doi.org/10.11250/chemotherapy1953.41.Supplement1_448
Publication status	Published - Jan 1 1993

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.41.Supplement1_448

Cite this

@article{4cb54b79e89540a48b5cd4b100bf95fd,

title = "Basic and clinical studies on S-1108 in urinary tract infections",

abstract = "We studied the antibacterial activity and efficacy of S-1108, a new cephem antibiotic, in urinary tract infections. 1) Antibacterial activity : The MICs of S-1006 were measured against 202 clinical isolates of 14 species from urinary tract infections and compared with those of cefaclor (CCL), cefixime (CFIX) and cefteram (CFTM). In general, the antibacterial activity of S-1006 was almost equal to that of CFIX and CFTM, but superior to that of CCL. 2) Clinical efficacy : According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 84.2% (16/19) for chronic complicated UTI. Bacteriologically, 21 of the 22 strains isolated (95.4%) were eradicated. 3) Side effects : No clinical adverse reactions and no abnormal laboratory findings were observed.",

author = "Noriaki Ono and Toyohiko Watanabe and Tadasu Takenaka and Toshihide Hayashi and Kazuhiro Hata and Hiromi Kumon and Hiroyuki Ohmori and Katsuiehi Nanba and Yoshikatsu Kondou and Teruhisa Ohhashi and Teruaki Akaeda",

year = "1993",

month = jan,

day = "1",

doi = "10.11250/chemotherapy1953.41.Supplement1_448",

language = "English",

volume = "41",

pages = "448--455",

journal = "Chemotherapy",

issn = "0009-3165",

}

TY - JOUR

T1 - Basic and clinical studies on S-1108 in urinary tract infections

AU - Ono, Noriaki

AU - Watanabe, Toyohiko

AU - Takenaka, Tadasu

AU - Hayashi, Toshihide

AU - Hata, Kazuhiro

AU - Kumon, Hiromi

AU - Ohmori, Hiroyuki

AU - Nanba, Katsuiehi

AU - Kondou, Yoshikatsu

AU - Ohhashi, Teruhisa

AU - Akaeda, Teruaki

PY - 1993/1/1

Y1 - 1993/1/1

N2 - We studied the antibacterial activity and efficacy of S-1108, a new cephem antibiotic, in urinary tract infections. 1) Antibacterial activity : The MICs of S-1006 were measured against 202 clinical isolates of 14 species from urinary tract infections and compared with those of cefaclor (CCL), cefixime (CFIX) and cefteram (CFTM). In general, the antibacterial activity of S-1006 was almost equal to that of CFIX and CFTM, but superior to that of CCL. 2) Clinical efficacy : According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 84.2% (16/19) for chronic complicated UTI. Bacteriologically, 21 of the 22 strains isolated (95.4%) were eradicated. 3) Side effects : No clinical adverse reactions and no abnormal laboratory findings were observed.

AB - We studied the antibacterial activity and efficacy of S-1108, a new cephem antibiotic, in urinary tract infections. 1) Antibacterial activity : The MICs of S-1006 were measured against 202 clinical isolates of 14 species from urinary tract infections and compared with those of cefaclor (CCL), cefixime (CFIX) and cefteram (CFTM). In general, the antibacterial activity of S-1006 was almost equal to that of CFIX and CFTM, but superior to that of CCL. 2) Clinical efficacy : According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 84.2% (16/19) for chronic complicated UTI. Bacteriologically, 21 of the 22 strains isolated (95.4%) were eradicated. 3) Side effects : No clinical adverse reactions and no abnormal laboratory findings were observed.

UR - http://www.scopus.com/inward/record.url?scp=0027179111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027179111&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.41.Supplement1_448

DO - 10.11250/chemotherapy1953.41.Supplement1_448

M3 - Article

AN - SCOPUS:0027179111

SN - 0009-3165

VL - 41

SP - 448

EP - 455

JO - Chemotherapy

JF - Chemotherapy

ER -

Basic and clinical studies on S-1108 in urinary tract infections

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this